Sep 2026
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.
R. Galot, Z. Castel-Ajgal, N. Kotecki et al.
· Investigational new drugs · 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Open access
Sep 2026
Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma
Background Intratumoral heterogeneity (ITH) is thought to contribute to tumour evolution and treatment resistance but its biological and clinical significance in localised head and neck squamous-cell carcinoma (HNSCC) remains incompletely understood. Patients and methods In the prospective SCANDARE study, we analysed 8...
V. Heurtier, G. Marret, C. Lamy et al.
· ESMO Open · 0 citations